RxSight Inc. (RXST)

Market Closed

10 Sep, 20:00

NASDAQ (NMS)

5. 96

-0.37

-5.8452%

Pre Market

6. 00

+0.04 +0.6711%

267.01M Market Cap

- P/E Ratio

- Div Yield

665,913 Volume

-0.9 Eps

$ 6.33

Previous Close

Investors:

+14

Analysts:

Add Transaction

Day Range

5.9 6.26

Year Range

4.48 13.22

Want to track RXST and more in your Portfolio? 🎯

Get Started For Free

RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript

Seekingalpha | 1 month ago

RxSight Q2 Earnings Call Highlights

RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.

Marketbeat | 1 month ago

RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.08 per share a year ago.

Zacks | 1 month ago

Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 month ago

RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?

RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks | 1 month ago

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight NASDAQ: RXST reported preliminary second-quarter financial results and provided updates on its product pipeline following a newly announced strategic collaboration agreement with Alcon, with management pointing to both near-term commercial headwinds and longer-term opportunities in adjustable intraocular lenses.

Marketbeat | 2 months ago

RxSight: After Dropping To The Bottom, It's Time To Pick It Up

RxSight, Inc. exhibits quantitative similarities to other small caps that I have rated here on Seeking Alpha that strongly outperformed the market. RXST is an 'NCAV' opportunity, a company that sells for less than its current asset value even though management is putting the company back on the growth track. My thesis is grounded in historical patterns where cash-rich, loss-making small caps often resolve operational issues before exhausting reserves.

Seekingalpha | 2 months ago